<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24068154</article-id>
      <article-id pub-id-type="pmc">3760958</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131905</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Off-label use of rituximab in dermatology: pemphigus
treatment<xref ref-type="fn" rid="fn01">*</xref></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Uso off-label do rituximab na dermatologia: tratamento dos
p&#xEA;nfigos</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bomm</surname>
            <given-names>Lislaine</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fracaroli</surname>
            <given-names>Tain&#xE1; Scalfoni</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sodr&#xE9;</surname>
            <given-names>Jo&#xE3;o Luz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bressan</surname>
            <given-names>Aline</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gripp</surname>
            <given-names>Alexandre Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD. Medical resident of dermatology at the University Hospital Pedro Ernesto - State University of Rio de Janeiro (HUPE-UERJ) -
Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff02"><label>2</label> MD. Medical graduate student in dermatology at the Pedro Ernesto University Hospital - University of the State of Rio de Janeiro
(HUPE-UERJ) - Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff03"><label>3</label> MD. Dermatologist - physician at the Biological and Immunosuppressants Clinic of the Pedro Ernesto University Hospital - University of the State of Rio de Janeiro (HUPE-UERJ) - Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff04"><label>4</label> MD. Dermatologist - Hospital assistant and preceptor of outpatient dermatology - immunosuppressive and biological agents Pedro Ernesto University Hospital - University of the State of Rio de Janeiro (HUPE-UERJ) - Rio de Janeiro (RJ), Brazil.
</aff>
      <author-notes>
        <corresp id="c01"><bold>MAILING ADDRESS:</bold> Lislaine Bomm, Boulevard 28 de setembro, 66 20551-030 -
Rio de Janeiro - RJ, Brazil, E-mail: <email>lislainebomm@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>4</issue>
      <fpage>676</fpage>
      <lpage>678</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>5</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>7</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Since its approval in 1997 by the FDA (United States Food and Drug Administration),
rituximab has been used for certain B-cell lymphomas and treatment-resistant
rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have
demonstrated the efficacy of off-label rituximab in several dermatological
inflammatory conditions. This study describes two cases of pemphigus vulgaris and two
cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a
week for 4 weeks, and that responded well to treatment.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Desde a sua aprova&#xE7;&#xE3;o em 1997 pela FDA (United States Food and Drug Administration),
o rituximab tem sido utilizado para o tratamento de alguns linfomas de c&#xE9;lulas B e da
artrite reumatoide resistente &#xE0; terapia convencional. Por&#xE9;m, ao longo dos &#xFA;ltimos 14
anos, muitos relatos demonstraram a efic&#xE1;cia do uso off-label do rituximab em v&#xE1;rias
afec&#xE7;&#xF5;es dermatol&#xF3;gicas. Neste estudo, relatamos dois casos de p&#xEA;nfigo vulgar e dois
casos de p&#xEA;nfigo foli&#xE1;ceo que foram tratados com rituximab, na dose de 375 mg/m2 uma
vez por semana durante 4 semanas, e que apresentaram boa resposta ao tratamento.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>biological treatment</kwd>
        <kwd>immunosuppressive agents</kwd>
        <kwd>pemphigus</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Rituximab is a murine-human chimeric monoclonal antibody against CD20 that induces the
depletion of B-cells in vivo. Rituximab acts at the CD20 receptor. CD20 is expressed
specifically on the surface of B lymphocytes throughout differentiation, from the
pre-B-cell to mature B-cell stage, but not on plasma cells or stem cells.<sup><xref ref-type="bibr" rid="B01">1</xref></sup> This differential expression might explain why serum
immunoglobulin levels do not decrease after treatment and why B-cells typically begin
recirculating within 6 months of therapy. Rituximab binds human complement, affecting complement-dependent cell lysis and
antibody-dependent cellular cytotoxicity, and can disrupt signaling pathways and trigger
apoptosis. <sup><xref ref-type="bibr" rid="B02">2</xref></sup>
</p>
    <p>Its FDA-approved indications are only for nonresponsive or relapsed rheumatoid arthritis
and lowgrade follicular CD20+ lymphoma. However, off-label applications for autoimmune
diseases, such as pemphigus, systemic lupus erythematosus, and angioedema, have emerged in
recent years.</p>
    <p>There are two officially approved dosages of rituximab. In non-Hodgkin lymphoma, rituximab
is given as an IV infusion of 375 mg/m<sup><xref ref-type="bibr" rid="B02">2</xref></sup> once weekly
for 4-8 consecutive weeks as a single agent or in combination with chemotherapy regimens.
In rheumatoid arthritis, the dosage is 2 IV infusions of 1000 mg given 2 weeks apart (days
1 and 15), along with methotrexate. In pemphigus vulgaris, the off-label protocol in the
literature is a 375-mg/m<sup><xref ref-type="bibr" rid="B02">2</xref></sup> IV infusion once weekly
for 2-4 consecutive weeks. Another option is 375 mg/m<sup><xref ref-type="bibr" rid="B02">2</xref></sup> IV once weekly for 8 consecutive weeks with 1 cycle of 2 mg/kg IVIG during
weeks 4 and 8, followed by a monthly dose of rituximab and IVIG cycles for 4 consecutive
months.<sup><xref ref-type="bibr" rid="B03">3</xref></sup>
</p>
    <p>Pemphigus is an autoimmune blistering disease that affects the skin and mucous membranes,
caused by circulating autoantibodies directed against desmogleins, which encompass
desmosomal proteins that mediate keratinocyte adhesion. The binding of autoantibodies
results in the loss of cell-cell adhesion and blister formation. Systemic steroids, in
combination with immunosuppressive agents, are the mainstay of therapy in pemphigus and
have dramatically improved the prognosis, but the adverse effects and complications from
long-term therapy still contribute substantially to its morbidity and mortality.
Alternative treatments such as pulse therapy with high doses of intravenous steroids,
cyclophosphamide, azathioprine, human intravenous immunoglobulin, plasmapheresis and
mycophenolate mofetil, can be used to positive effect.<sup><xref ref-type="bibr" rid="B04">4</xref></sup> However, some patients remain refractory to treatment, even when used in
combination or rotation. In refractory and clinical rapidly progressive cases we believe
the use of rituximab may be beneficial, leading to a longer remission of the disease and
faster clinical improvement, respectively.</p>
    <p>We present four cases of pemphigus treated with rituximab, taking into regard
refractoriness to conventional treatments or clinical rapidly progressive cases. <xref ref-type="table" rid="t01">Table 1</xref>
shows the clinical data of these patients, including the age, sex, adjuvant, and assessment
after infusion, with adverse effects, response, monitoring, and maintenance therapy.
Patient number 1 had pemphigus vulgaris with a rapid and progressive evolution, with
extensive mucosal involvement that did not respond to systemic corticosteroids taken in
high doses (pulses of methylprednisolone 30mg/kg and prednisone 1-2mg/kg) (<xref ref-type="fig" rid="f01">Figure 1A</xref>). The use of rituximab brought about
improvement within 15 days and the patient remained in remission for two and a half years,
when he presented new mucosal lesions, but they were less intense and easily controlled
with steroids (<xref ref-type="fig" rid="f01">Figure 1B</xref>). The other patients remain
without disease activity, with gradual reduction of maintenance medication (Azatioprine
12mg/kg, in gradual reduction) except patient number 2 who is in complete remission without
medication. We observed that patients with pemphigus foliaceus had a slower response to
therapy, which is also the case with other therapies, but we found no justification for
this in the literature.</p>
    <table-wrap id="t01" orientation="portrait" position="float">
      <label>TABLE 1</label>
      <caption>
        <p>Comparison of laboratory tests of 15 patients with psoriasis followed up in an
outpatient clinic, before and after the use of immunobiologicals</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>Patient/Sex/Age years</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Pemphigus Type</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Adjuvant Therapy</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Adverse Effects (weeks)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Response after Rituximab infusion</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Follow-up (months)</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>Maintenance Therapy</bold>
            </td>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">1/M/50 (<xref ref-type="fig" rid="f01">Figure 1A</xref> and <xref ref-type="fig" rid="f01">1B</xref>)</td>
            <td rowspan="1" colspan="1">PV<sup><xref ref-type="table-fn" rid="t01-fn01">*</xref></sup></td>
            <td rowspan="1" colspan="1">Prednisone 80mg/ day + Azathioprine 150 mg/day</td>
            <td align="center" rowspan="1" colspan="1">no effects</td>
            <td align="center" rowspan="1" colspan="1">2</td>
            <td align="center" rowspan="1" colspan="1">24</td>
            <td rowspan="1" colspan="1">Azathioprine</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">2/M/18</td>
            <td rowspan="1" colspan="1">PF<sup><xref ref-type="table-fn" rid="t01-fn02">**</xref></sup></td>
            <td rowspan="1" colspan="1">Azathioprine 150 mg/day</td>
            <td align="center" rowspan="1" colspan="1">no effects</td>
            <td align="center" rowspan="1" colspan="1">20</td>
            <td align="center" rowspan="1" colspan="1">11</td>
            <td rowspan="1" colspan="1">Azathioprine</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">3/F/31</td>
            <td rowspan="1" colspan="1">PV</td>
            <td rowspan="1" colspan="1">Prednisone 60mg/day + Azathioprine 150 mg/day</td>
            <td align="center" rowspan="1" colspan="1">no effects</td>
            <td align="center" rowspan="1" colspan="1">12</td>
            <td align="center" rowspan="1" colspan="1">8</td>
            <td rowspan="1" colspan="1">Prednisone 20mg/day + Azathioprine</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">4/M/35</td>
            <td rowspan="1" colspan="1">PF</td>
            <td rowspan="1" colspan="1">Prednisone 50mg/day</td>
            <td align="center" rowspan="1" colspan="1">no effects</td>
            <td align="center" rowspan="1" colspan="1">24</td>
            <td align="center" rowspan="1" colspan="1">11</td>
            <td rowspan="1" colspan="1">Azathioprine</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="t01-fn01">
          <label>*</label>
          <p><bold>PV -</bold> pemphigus vulgaris</p>
        </fn>
        <fn id="t01-fn02">
          <label>**</label>
          <p><bold>PF -</bold> pemphigus foliaceus</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <fig id="f01" fig-type="other" orientation="portrait" position="float">
      <label>FIGURE 1</label>
      <caption>
        <p><bold>A.</bold> Patient with pemphigus vulgaris before the use of rituximab;
<bold>B.</bold> Patient with pemphigus vulgaris after the use of rituximab</p>
      </caption>
      <graphic xlink:href="abd-88-0676-g01"/>
    </fig>
    <p>Serious adverse reactions to rituximab are very rare. They include: angina, adverse drug
reactions, intestinal obstruction, lymphocytopenia, anemia, recurrent hepatitis B,
progressive multifocal leukoencephalopathy, etc. The most common adverse effects are
associated with infusion reactions, often related to the speed of administration and immune
hypersensitivity reactions (fever, chills, bronchospasm, pruritus, hypotension and
infection).<sup><xref ref-type="bibr" rid="B05">5</xref>,<xref ref-type="bibr" rid="B06">6</xref></sup> The cytokine-release syndrome can develop in
patients receiving rituximab for lymphoma and is most common in patients with bulky
adenopathy or bone marrow involvement. Although none of the patients in our study experienced these serious side effects, the
long-term consequences of rituximab therapy in patients with autoimmune diseases are
unknown. These findings underscore the need for further study of this drug to optimize its
efficacy and safety in dermatology.</p>
    <p>Therefore, rituximab is an emerging therapy for many autoimmune diseases such as pemphigus
and connective tissue diseases. In these cases, off-label alternative treatment remains an
option, especially for recalcitrant and rapidly progressive cases, or when conventional
therapy is contraindicated.<sup><xref ref-type="bibr" rid="B07">7</xref></sup> However, further
prospective, controlled studies are needed to determine the effective dose, the role of
adjuvant therapies, and to determine whether B cells depleted for an extended period may be
the mechanism to achieve long-term clinical remission. It is also necessary to evaluate the
cost-effectiveness of long-term treatment since 4 applications of 375mg/m<sup><xref ref-type="bibr" rid="B02">2</xref></sup> cost on average 16 thousand dollars.</p>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work conducted at the Pedro Ernesto University Hospital - State University of Rio
de Janeiro (HUPE-UERJ) - Rio de Janeiro (RJ), Brasil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carr</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Heffernan</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Off-label uses of rituximab in
dermatology</article-title>
          <source>Dermatol Ther</source>
          <year>2007</year>
          <volume>20</volume>
          <fpage>277</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">17970893</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fatourechi</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>el-Azhary</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Rituximab: applications in dermatology</article-title>
          <source>Int J Dermatol</source>
          <year>2006</year>
          <volume>45</volume>
          <fpage>1143</fpage>
          <lpage>1155</lpage>
          <pub-id pub-id-type="pmid">17040427</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emer</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wolinsky</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Rituximab: a review of dermatological
applications</article-title>
          <source>J Clin Aesthet Dermatol</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>29</fpage>
          <lpage>37</lpage>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cianchini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Corona</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Frezzolini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ruffelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Didona</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Puddu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Treatment of severe pemphigus with
rituximab</article-title>
          <source>Arch Dermatol</source>
          <year>2007</year>
          <volume>143</volume>
          <fpage>1033</fpage>
          <lpage>1038</lpage>
          <pub-id pub-id-type="pmid">17709662</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diab</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Galina</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Treatment of refractory pemphigus erythematosus with
rituximab</article-title>
          <source>Int J Dermatol</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>1317</fpage>
          <lpage>1318</lpage>
          <pub-id pub-id-type="pmid">19126029</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Wolverton</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>The efficacy and safety of rituximab in refractory
pemphigus: a review of case reports</article-title>
          <source>J Drugs Dermatol</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>883</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="pmid">17941359</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Baur</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Siebenhaar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wenzel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Eming</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Targeted immunotherapy with rituximab leads to a
transient alteration of the IgG autoantibody profile in pemphigus
vulgaris</article-title>
          <source>Dermatol Res Pract</source>
          <year>2010</year>
          <volume>2010</volume>
          <fpage>321950</fpage>
          <lpage>321950</lpage>
          <pub-id pub-id-type="doi">10.1155/2010/321950</pub-id>
          <pub-id pub-id-type="pmid">20671975</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
